Evidence map›Paper›PMID 40136373›Full record

Trial reportCurrent oncology (Toronto, Ont.)2025

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer.

Hope S Rugo, Aditya Bardia, Peter Schmid, Sara M Tolaney, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Marine Gosset, Adam Brufsky, Javier Cortés and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Genomic Predictive Biomarkers in Breast Cancer: TheInternational journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hope S RugoHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA.ORCID 0000-0001-6710-4814
Aditya BardiaJonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Peter SchmidCentre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Sara M TolaneyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-5940-8671
Anandaroop DasguptaGilead Sciences, Inc., Foster City, CA 94404, USA.
Ankita KaushikGilead Sciences, Inc., Foster City, CA 94404, USA.
Wendy VerretGilead Sciences, Inc., Foster City, CA 94404, USA.
Marine GossetEvidera, 94853 Paris, France.
Adam BrufskyMagee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.ORCID 0000-0001-8080-7960
Javier CortésQuirónsalud Group, Pangaea Oncology, International Breast Cancer Center (IBCC), 08028 Barcelona, Spain.ORCID 0000-0001-7623-1583
Frederik MarméMedical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0002-6591-3367

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Gilead Sciences, Inc NANCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

In TROPiCS-02, sacituzumab govitecan (SG) demonstrated significantly longer overall survival and progression-free survival with improved quality of life vs. chemotherapy treatment of physician's choice (TPC) in patients with HR+/HER2- metastatic breast cancer (mBC). The safety profile was consistent with previous studies of SG. We assessed the benefit--risk profile of SG vs. TPC by integrating patient preferences with clinical benefits using Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) analysis in this study population. Survival time was partitioned into three health states: TOX (grade ≥3 treatment-emergent adverse events [TEAEs] after randomization/before disease progression), REL (disease progression until death or end of follow-up), and TWiST (time without progression or grade ≥3 TEAEs). Health state utility weights were obtained from the published literature. The established threshold for clinically important Q-TWiST gain is 10%. SG demonstrated significantly improved Q-TWiST vs. TPC (mean 9.7 vs. 8.1 months; difference 1.6 months; 95% CI, 0.5-2.7;

Indexed as

Antibodies, Monoclonal, HumanizedBreast NeoplasmsCamptothecinSingle-Domain AntibodiesErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunoconjugatesMiddle AgedNeoplasm MetastasisQuality of LifeAntibodies, Monoclonal, HumanizedCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatessacituzumab govitecanSingle-Domain Antibodiesantibody-drug conjugatebreast cancerHR+/HER2−Q-TWiSTquality of lifesacituzumab govitecan

Identifiers

PMID40136373
PMCPMC11941552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.